aod9604 human trials weight loss evidence clinical Fat loss isn't one process. It's three. And scientists aod9604 human clinical trials results

Subcutaneous (SQ) or Intramuscular (IM)

2) Treatment with AOD9604 has been found to increase expression of beta-3-AR RNA, indicating that the compound has the potential to enhance lipolytic sensitivity

A molecule that is not what its label claims is not simply ineffective, it is a genuine safety concern, because you cannot know what you are actually putting into your body

The researchers own conclusion was that it was well absorbed. Why that number is the whole ballgame: ~38% of an oral dose reaching circulation is a genuinely good absorption fraction for an oral compound plenty of approved oral products sit at or below that

FDA in 2014